The Readout Loud 365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
19 snips
Aug 14, 2025 Marissa Russo, a STAT fellow and PhD candidate at the Mayo Clinic focusing on glioblastoma, joins to delve into the hotly debated topic of alternatives to animal testing. She explores the innovative methodologies like organ-on-chip models and the push from the FDA and NIH towards more humane research practices. The conversation also touches on the complexities of these new approaches and the challenges in ensuring their reliability. Additionally, insights on the shifting landscape of mRNA technology add to the discussion's depth.
AI Snips
Chapters
Transcript
Episode notes
mRNA Vaccines Face Political Headwinds
- HHS cuts to BARDA grants and political shifts have chilled investment in mRNA vaccines specifically.
- mRNA therapeutics remain attractive and startups are pivoting toward therapeutic uses like cancer vaccines.
Pivot From Vaccines To Therapeutics
- Companies developing mRNA vaccines should consider pivoting toward therapeutics to retain investor interest and regulatory momentum.
- Expect some vaccine-focused startups to fold while others reallocate resources to therapeutic programs.
Lab Space Empties As Layoffs Continue
- The biotech sector faces prolonged strain with widespread layoffs and vacant lab space even in hubs like Kendall Square.
- Companies are extending cash runs and reprioritizing pipelines to survive uncertain funding conditions.